Our top pick for
NovoCure Limited is a medical instruments & supplies business based in the US. NovoCure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. NovoCure employs 782 staff and has a trailing 12-month revenue of around USD$449.6 million.
|Latest market close||USD$170.09|
|52-week range||USD$53.4 - USD$180.97|
|50-day moving average||USD$156.8385|
|200-day moving average||USD$110.6133|
|Wall St. target price||USD$136|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.184|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||3.97%|
|1 month (2020-12-17)||4.47%|
|3 months (2020-10-16)||24.19%|
|6 months (2020-07-17)||169.39%|
|1 year (2020-01-17)||83.72%|
|2 years (2019-01-17)||275.72%|
|3 years (2018-01-17)||719.71%|
|5 years (2016-01-15)||856.10%|
Valuing NovoCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NovoCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NovoCure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 955x. In other words, NovoCure shares trade at around 955x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NovoCure's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$26.3 million.
The EBITDA is a measure of a NovoCure's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$449.6 million|
|Operating margin TTM||4.18%|
|Gross profit TTM||USD$263 million|
|Return on assets TTM||2.68%|
|Return on equity TTM||7.7%|
|Market capitalisation||USD$17.9 billion|
TTM: trailing 12 months
There are currently 5.9 million NovoCure shares held short by investors – that's known as NovoCure's "short interest". This figure is 17.8% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting NovoCure shares can be evaluated.
NovoCure's "short interest ratio" (SIR) is the quantity of NovoCure shares currently shorted divided by the average quantity of NovoCure shares traded daily (recently around 1.5 million). NovoCure's SIR currently stands at 3.95. In other words for every 100,000 NovoCure shares traded daily on the market, roughly 3950 shares are currently held short.
However NovoCure's short interest can also be evaluated against the total number of NovoCure shares, or, against the total number of tradable NovoCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NovoCure's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NovoCure shares in existence, roughly 50 shares are currently held short) or 0.0608% of the tradable shares (for every 100,000 tradable NovoCure shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NovoCure.
Find out more about how you can short NovoCure stock.
We're not expecting NovoCure to pay a dividend over the next 12 months.
Over the last 12 months, NovoCure's shares have ranged in value from as little as $53.4 up to $180.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NovoCure's is 1.2836. This would suggest that NovoCure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.